NG2 and DLL3 CAR-T Cells Targeting Melanoma

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT07193966
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • NG2 and DLL3 CAR-T cells — BIOLOGICAL
    Infusion of NG2 and DLL3-specific CAR-T via intravenous route

Study Details

The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.

Key Dates

First listed
Sep 26, 2025
Start date
Sep 1, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: effectiveness of CAR-T cells targeting NG2 and DLL3
    Gene-modified T cells are designed to kill tumor cells through specific recognition of NG2 and DLL3. This study will evaluate the side effects and effective doses of NG2 and DLL3 CAR-T cells in treating refractory and recurrent melanoma

Primary Outcome Measure

Number of patients with adverse events. [ Time Frame: 3 months ]

Central Contacts

Find similar trials

Nationwide
Melanoma trialsOncology trialsSkin cancer trialsDermatology trials

Related Studies